Analyst Rating Update on Hologic (HOLX)

Hologic (NASDAQ:HOLX) : The consensus on Hologic (NASDAQ:HOLX) based on 16 analyst recommendation on the company stock is 1.88, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Hologic (NASDAQ:HOLX) stock is expected to deviate a maximum of $2.56 from the average target price of $42.25 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $46 and the most muted being $38.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Needham downgrades its ratings on Hologic (NASDAQ:HOLX). According to the latest information available, the shares are now rated Hold by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on April 28, 2016.

Hologic (NASDAQ:HOLX): stock turned positive on Tuesday. Though the stock opened at $33.03, the bulls momentum made the stock top out at $33.42 level for the day. The stock recorded a low of $32.99 and closed the trading day at $33.35, in the green by 1.28%. The total traded volume for the day was 2,283,844. The stock had closed at $32.93 in the previous days trading.

In an insider trading activity,The director of Hologic Inc, Levy Lawrence M sold 17,794 shares at $34.41 on June 1, 2016. The Insider selling transaction had a total value worth of $612,292. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.